HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
More US tech stocks look cheap as the market rotates
stocks
Earnings Losers: GYG, DMP & LLC slump on souring market sentiment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,401.00 | 19.50 | -0.21% |
| CAC 40 | 8,580.75 | 40.18 | -0.47% |
| DAX 40 | 25,284.26 | 4.76 | -0.02% |
| Dow JONES (US) | 48,977.92 | 521.28 | -1.05% |
| FTSE 100 | 10,910.55 | 63.85 | 0.59% |
| HKSE | 26,162.61 | 218.41 | -0.83% |
| NASDAQ | 22,668.21 | 210.17 | -0.92% |
| Nikkei 225 | 57,948.26 | 805.13 | -1.37% |
| NZX 50 Index | 13,622.41 | 48.30 | -0.35% |
| S&P 500 | 6,878.88 | 29.98 | -0.43% |
| S&P/ASX 200 | 9,170.90 | 10.80 | -0.12% |
| SSE Composite Index | 4,162.85 | 0.03 | -0.00% |